ProShare Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $345K | Sell |
23,251
-4,390
| -16% | -$64.2K | ﹤0.01% | 1270 |
|
|
2025
Q4 | $441K | Buy |
27,641
+3,039
| +12% | +$43.1K | ﹤0.01% | 1201 |
|
|
2025
Q3 | $272K | Sell |
24,602
-4,597
| -16% | -$50.2K | ﹤0.01% | 1498 |
|
|
2025
Q2 | $247K | Sell |
29,199
-6,057
| -17% | -$48.6K | ﹤0.01% | 1579 |
|
|
2025
Q1 | $283K | Sell |
35,256
-9,332
| -21% | -$75.6K | ﹤0.01% | 1450 |
|
|
2024
Q4 | $400K | Buy |
44,588
+10,771
| +32% | +$87.9K | ﹤0.01% | 1417 |
|
|
2024
Q3 | $248K | Buy |
33,817
+6,850
| +25% | +$42.5K | ﹤0.01% | 1590 |
|
|
2024
Q2 | $154K | Sell |
26,967
-7,497
| -22% | -$39.5K | ﹤0.01% | 1587 |
|
|
2024
Q1 | $173K | Buy |
34,464
+2,873
| +9% | +$19.5K | ﹤0.01% | 1707 |
|
|
2023
Q4 | $284K | Buy |
31,591
+4,624
| +17% | +$38.1K | ﹤0.01% | 1425 |
|
|
2023
Q3 | $210K | Buy |
26,967
+100
| +0.4% | +$978 | ﹤0.01% | 1436 |
|
|
2023
Q2 | $260K | Buy |
26,867
+1,194
| +5% | +$12.4K | ﹤0.01% | 1365 |
|
|
2023
Q1 | $281K | Sell |
25,673
-3,341
| -12% | -$29.4K | ﹤0.01% | 1251 |
|
|
2022
Q4 | $125K | Buy |
29,014
+2,290
| +9% | +$13.3K | ﹤0.01% | 1599 |
|
|
2022
Q3 | $202K | Buy |
26,724
+620
| +2% | +$5.37K | ﹤0.01% | 1403 |
|
|
2022
Q2 | $262K | Buy |
26,104
+11,444
| +78% | +$128K | ﹤0.01% | 1290 |
|
|
2022
Q1 | $181K | Sell |
14,660
-3,601
| -20% | -$55.7K | ﹤0.01% | 1906 |
|
|
2021
Q4 | $418K | Sell |
18,261
-9,168
| -33% | -$217K | ﹤0.01% | 1578 |
|
|
2021
Q3 | $607K | Buy |
27,429
+4,402
| +19% | +$69.9K | ﹤0.01% | 1094 |
|
|
2021
Q2 | $298K | Buy |
23,027
+5,394
| +31% | +$68.7K | ﹤0.01% | 1903 |
|
|
2021
Q1 | $229K | Sell |
17,633
-1,900
| -10% | -$27.6K | ﹤0.01% | 1961 |
|
|
2020
Q4 | $270K | Sell |
19,533
-812
| -4% | -$11.8K | ﹤0.01% | 1675 |
|
|
2020
Q3 | $300K | Buy |
20,345
+2,347
| +13% | +$34K | ﹤0.01% | 1174 |
|
|
2020
Q2 | $292K | Buy |
17,998
+3,235
| +22% | +$51.8K | ﹤0.01% | 1244 |
|
|
2020
Q1 | $214K | Sell |
14,763
-5,634
| -28% | -$99.4K | ﹤0.01% | 986 |
|
|
2019
Q4 | $413K | Sell |
20,397
-4,453
| -18% | -$41K | ﹤0.01% | 1164 |
|
|
2019
Q3 | $133K | Sell |
24,850
-1,979
| -7% | -$12K | ﹤0.01% | 1509 |
|
|
2019
Q2 | $177K | Sell |
26,829
-2,156
| -7% | -$13.7K | ﹤0.01% | 1462 |
|
|
2019
Q1 | $188K | Buy |
28,985
+62
| +0.2% | +$411 | ﹤0.01% | 1488 |
|
|
2018
Q4 | $197K | Sell |
28,923
-5,415
| -16% | -$31.2K | ﹤0.01% | 1378 |
|
|
2018
Q3 | $228K | Sell |
34,338
-1,046
| -3% | -$5.87K | ﹤0.01% | 1517 |
|
|
2018
Q2 | $199K | Sell |
35,384
-3,477
| -9% | -$19.4K | ﹤0.01% | 1614 |
|
|
2018
Q1 | $202K | Buy |
38,861
+10,078
| +35% | +$53.9K | ﹤0.01% | 1542 |
|
|
2017
Q4 | $130K | Buy |
+28,783
| New | +$160K | ﹤0.01% | 1710 |
|
Other funds holding AUPH
TCM
NMC
ProShare Advisors's AUPH Position: Q1 2026 in Review
ProShare Advisors reduced its Aurinia Pharmaceuticals (AUPH) stake by 16% in Q1 2026, selling an estimated $64.2K and leaving 23,251 shares worth $345K. The position accounts for ﹤0.01% of the portfolio, ranked #1270.
ProShare Advisors first reported a position in AUPH in Q4 2017 and has held it in 34 quarters since. The position peaked at $607K in Q3 2021. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.
- ProShare Advisors held 23,251 shares of Aurinia Pharmaceuticals worth $345K as of Q1 2026.
- ProShare Advisors sold 4,390 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $64.2K.
- Aurinia Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1270 holding.
- ProShare Advisors first reported a position in Aurinia Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- ProShare Advisors's Aurinia Pharmaceuticals position peaked at $607K in Q3 2021.
- 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.
Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.